Blueprint Medicines (BPMC) Scheduled to Post Earnings on Wednesday

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Wednesday, October 30th. Analysts expect Blueprint Medicines to post earnings of ($1.00) per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.49. The firm had revenue of $138.20 million during the quarter, compared to the consensus estimate of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The company's quarterly revenue was up 139.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.19) EPS. On average, analysts expect Blueprint Medicines to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Blueprint Medicines Price Performance

NASDAQ:BPMC traded down $2.07 during trading hours on Wednesday, reaching $84.40. 434,971 shares of the company traded hands, compared to its average volume of 687,694. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. The firm's 50-day moving average is $90.20 and its 200-day moving average is $98.76. The stock has a market cap of $5.28 billion, a P/E ratio of -17.98 and a beta of 0.58. Blueprint Medicines has a 1-year low of $43.89 and a 1-year high of $121.90.

Insider Buying and Selling

In related news, insider Fouad Namouni sold 3,633 shares of the firm's stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now directly owns 69,070 shares in the company, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now owns 69,070 shares of the company's stock, valued at $6,169,332.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Philina Lee sold 41,913 shares of the business's stock in a transaction on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the transaction, the insider now owns 34,729 shares in the company, valued at $3,236,395.51. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently commented on BPMC shares. Baird R W upgraded Blueprint Medicines to a "strong-buy" rating in a research report on Friday, August 2nd. Morgan Stanley upped their price objective on shares of Blueprint Medicines from $110.00 to $115.00 and gave the company an "equal weight" rating in a research note on Friday, July 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $130.00 target price on shares of Blueprint Medicines in a research note on Thursday, August 1st. Guggenheim increased their price target on Blueprint Medicines from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Finally, Robert W. Baird raised their price objective on Blueprint Medicines from $112.00 to $127.00 and gave the stock an "outperform" rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Blueprint Medicines presently has a consensus rating of "Moderate Buy" and a consensus price target of $120.00.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.